All Ords drug maker's shares plunge 30% on takeover troubles

Shares in this Australian drug maker have tumbled on news a takeover bid for the company could be blocked.

| More on:
Falling pills in a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cosette's takeover of Mayne Pharma could be block on national interest terms.
  • Cosette is already trying to get out of the deal.
  • Mayne shares fell sharply on the news.

Shares in Mayne Pharma Group Ltd (ASX: MYX) have fallen by more than 30% after it was revealed the federal government could step in to block a troubled potential takeover of the company.

US company Cosette Pharmaceuticals Inc launched a $7.40 per share takeover bid for Mayne in February, with the offer a 37% premium to the Mayne share price at the time.

But Cosette later tried to back out of the deal, arguing that there were a number of factors that constituted a "material adverse change" with regards to Mayne's business, including a trading update in April and certain correspondence with the US Food & Drug Administration (FDA).

Mayne denied Cosette's claims and took the matter to court, winning a ruling in the New South Wales Supreme Court recently, which denied Cosette's bid to back out of the deal.

Government could step in

But it has now emerged that Australian Treasurer Jim Chalmers could step in to block the deal on national interest terms.

Mayne told the ASX in a statement today that Mr Chalmers had written to Cosette, indicating that his "preliminary view is that the proposed acquisition would be contrary to the national interest, on the grounds that it would negatively impact the Australian economy and community".  

The statement goes on to say:

The letter states that the Treasurer is considering whether he should make orders prohibiting the acquisition contemplated by the Scheme. Treasury was advised that Cosette had re-evaluated its intentions concerning Mayne Pharma's business in Australia and determined that if Cosette were to acquire Mayne Pharma, its current intention is to seek to dispose of, or close, the manufacturing site in Adelaide.

The letter, Mayne said, went on to say that the Treasurer believed the company's Adelaide site was important to Australia's "pharmaceutical manufacturing and research and development capabilities".

Mayne said it agreed with the Treasurer regarding this view.

Given the valuable nature of the site, Mayne Pharma does not consider that it would be commercially rational to close the site and has consistently communicated this to Cosette since Cosette informed the Foreign Investment Review Board of its stated change of intention on 24 June 2025.

Mayne said the letter from the Treasurer had invited submissions from Cosette about his concerns, and the Australian company said that no final decision had been made by the Treasurer, meaning Cosette was still "obligated … to use its best endeavours to obtain the Treasurer's approval of the scheme''.

Mayne shares fell as low as $3.81 on the news before recovering to be 30.2% lower at $4.33 by mid-morning.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Sell and buy on red cubes on a digital screen.
Technology Shares

This ASX 200 high-flyer dropped 15%, is it time to jump in?

Analysts remain positive due to the company's strong fundamentals.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Healthcare Shares

Are CSL shares a buy after their heavy decline?

Let's see what one broker is saying about the biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares diving today?

Shares in this up-and-coming drug company are under pressure over law suits filed in the US.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Healthcare Shares

CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Down 38% in a year, are CSL shares now a buy?

A leading investment expert delivers his verdict on CSL shares.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Healthcare Shares

This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion

This company is looking to raise $125 million to help commercialise its epilepsy monitoring technology.

Read more »

Surgeon looking at a monitor in an operating room.
Share Market News

Is the only way up for this ASX small-cap healthcare stock?

Bigger returns could be coming for this ambitious small-cap.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Read more »